Liminatus Pharma (LIMN) Competitors $5.93 -0.34 (-5.42%) As of 08/1/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsSEC FilingsTrendsBuy This Stock LIMN vs. STOK, DAWN, ATAI, KALV, TNGX, MNMD, GYRE, MAZE, AVBP, and DNTHShould you be buying Liminatus Pharma stock or one of its competitors? The main competitors of Liminatus Pharma include Stoke Therapeutics (STOK), Day One Biopharmaceuticals (DAWN), atai Life Sciences (ATAI), KalVista Pharmaceuticals (KALV), Tango Therapeutics (TNGX), Mind Medicine (MindMed) (MNMD), Gyre Therapeutics (GYRE), Maze Therapeutics (MAZE), ArriVent BioPharma (AVBP), and Dianthus Therapeutics (DNTH). These companies are all part of the "pharmaceutical products" industry. Liminatus Pharma vs. Its Competitors Stoke Therapeutics Day One Biopharmaceuticals atai Life Sciences KalVista Pharmaceuticals Tango Therapeutics Mind Medicine (MindMed) Gyre Therapeutics Maze Therapeutics ArriVent BioPharma Dianthus Therapeutics Liminatus Pharma (NASDAQ:LIMN) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations. Is LIMN or STOK more profitable? Stoke Therapeutics has a net margin of 26.33% compared to Liminatus Pharma's net margin of 0.00%. Stoke Therapeutics' return on equity of 19.08% beat Liminatus Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Liminatus PharmaN/A N/A N/A Stoke Therapeutics 26.33%19.08%15.72% Does the media refer more to LIMN or STOK? In the previous week, Stoke Therapeutics had 2 more articles in the media than Liminatus Pharma. MarketBeat recorded 5 mentions for Stoke Therapeutics and 3 mentions for Liminatus Pharma. Stoke Therapeutics' average media sentiment score of 0.15 beat Liminatus Pharma's score of 0.03 indicating that Stoke Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liminatus Pharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Stoke Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate LIMN or STOK? Stoke Therapeutics has a consensus price target of $25.80, suggesting a potential upside of 99.85%. Given Stoke Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Stoke Therapeutics is more favorable than Liminatus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Stoke Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has higher valuation and earnings, LIMN or STOK? Liminatus Pharma has higher earnings, but lower revenue than Stoke Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLiminatus PharmaN/AN/AN/AN/AN/AStoke Therapeutics$36.56M19.28-$88.98M$0.7916.34 SummaryStoke Therapeutics beats Liminatus Pharma on 10 of the 10 factors compared between the two stocks. Get Liminatus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for LIMN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIMN vs. The Competition Export to ExcelMetricLiminatus PharmaBiological Products, Except Diagnostic Substances IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$163.11M$229.22M$2.21B$9.52BDividend YieldN/AN/A2.59%4.09%P/E RatioN/AN/A22.1423.81Price / SalesN/AN/A83.3066.04Price / CashN/AN/A26.0557.96Price / BookN/AN/A40.025.54Net IncomeN/AN/A-$62.28M$259.28M7 Day Performance-31.92%-13.67%-2.50%-4.64%1 Month Performance-32.69%18.99%-0.61%4.41%1 Year PerformanceN/A142.77%26.13%17.95% Liminatus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIMNLiminatus PharmaN/A$5.93-5.4%N/AN/A$163.11MN/A0.00N/ANews CoverageAnalyst DowngradeGap DownSTOKStoke Therapeutics4.0299 of 5 stars$12.87+3.0%$25.80+100.5%-12.3%$702.70M$36.56M16.29100Upcoming EarningsDAWNDay One Biopharmaceuticals2.2584 of 5 stars$6.87-1.7%$29.00+322.1%-53.1%$696.34M$131.16M-9.6860Upcoming EarningsATAIatai Life Sciences2.9973 of 5 stars$3.47+4.8%$11.25+224.2%+193.7%$695.17M$1.86M-3.8180Analyst ForecastShort Interest ↑Analyst RevisionGap DownKALVKalVista Pharmaceuticals3.8282 of 5 stars$13.84+0.7%$26.29+89.9%-4.5%$691.31MN/A-3.75100TNGXTango Therapeutics1.6428 of 5 stars$6.30-2.3%$10.50+66.7%-30.9%$682.88M$40.99M-5.1690Upcoming EarningsGap DownMNMDMind Medicine (MindMed)1.9119 of 5 stars$9.03-1.2%$24.00+165.8%+0.7%$682.22MN/A-7.0040News CoverageEarnings ReportAnalyst ForecastGYREGyre TherapeuticsN/A$7.27-0.4%N/A-52.4%$681.64M$105.76M363.6840MAZEMaze TherapeuticsN/A$15.50-1.5%$25.60+65.2%N/A$678.90M$167.50M0.00121Lockup ExpirationAVBPArriVent BioPharma1.6362 of 5 stars$19.59-3.2%$39.29+100.5%-13.2%$670.17MN/A-5.2040Positive NewsDNTHDianthus Therapeutics1.2494 of 5 stars$20.80-2.8%$53.00+154.8%-26.5%$668.93M$6.24M-7.2280Upcoming Earnings Related Companies and Tools Related Companies Stoke Therapeutics Competitors Day One Biopharmaceuticals Competitors atai Life Sciences Competitors KalVista Pharmaceuticals Competitors Tango Therapeutics Competitors Mind Medicine (MindMed) Competitors Gyre Therapeutics Competitors Maze Therapeutics Competitors ArriVent BioPharma Competitors Dianthus Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIMN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Liminatus Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Liminatus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LIMN Stock Alerts